CAS: 927961-18-0

Lanifibranor is a drug that has been shown to lower systolic pressure in diabetic patients. It is an antidiabetic agent that blocks the synthesis of fatty acids and triglycerides by inhibiting the enzyme protein kinase C (PKC). Lanifibranor has been shown to decrease the levels of fibrosis and cell nuclei, as well as decrease the proliferation of cells in culture. This drug also lowers body mass index and improves metabolic disorders in diabetic patients. Lanifibranor inhibits PKC, which leads to a reduction in primary cells such as liver cells and fibroblasts, thereby decreasing inflammation and oxidative stress. This drug is currently undergoing clinical trials for use in autoimmune diseases like celiac disease.